Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and TB-500 — mechanism, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to amino acids 17–23 of thymosin β4, the actin-binding region of the native 43-residue protein. Despite widespread vendor labeling, TB-500 is NOT identical to full-length thymosin β4 (Tβ4); it is a short fragment containing the central actin-binding motif. It is sold as a research chemical and is not FDA-approved for any human indication.
BPC-157
TB-500
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
TB-500
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
338
COAs
99.3%
Avg purity
16
Labs
TB-500
188
COAs
99.3%
Avg purity
16
Labs
BPC-157 and TB-500 are both among peptides under FDA review for the Category 1 (503A) list; if added, they would require a prescription to be compounded by registered 503A/503B pharmacies — they are not yet authorized. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
Animal studies of full-length Tβ4 show accelerated dermal wound reepithelialization (Malinda et al., 1999, PMID 10469335), increased angiogenesis, improved cardiac function after ischemic injury via an ILK/Akt pathway (Bock-Marquette et al., Nature 2004, PMID 15565145), and corneal healing (Sosne & Kleinman review, 2015, PMID 26241398). The short Ac-LKKTETQ peptide sold as TB-500 was characterized analytically in the anti-doping literature as a substance with suspected doping potential (Esposito et al., 2012, PMID 22962027); controlled human efficacy trials of injected TB-500 do not exist. Full-length synthetic Tβ4 (RGN-259) has been evaluated in Phase II/III ophthalmic trials for dry eye disease and neurotrophic keratopathy with mixed results — one Phase III NK trial met healing endpoints, while a later European Phase III missed its primary endpoint. No clinically validated human injection dose exists for the short TB-500 peptide; all circulating dosing figures derive from vendor and forum protocols, not controlled trials.
BPC-157 and TB-500 are both in the Recovery category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
Cheapest verified BPC-157: live prices, vendors & COA data
The cheapest verified BPC-157 by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 16 labs across 338 COAs.
Cheapest verified TB-500: live prices, vendors & COA data
The cheapest verified TB-500 by price-per-mg — a live board of in-stock vendors with COAs on file. Lab data from 16 labs across 166 COAs.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs